Navigation Links
Drugs used to treat osteoporosis not linked with higher risk of esophageal cancer
Date:8/10/2010

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

Bisphosphonates are mainly used to prevent or treat osteoporosis, especially in postmenopausal women. Their use has increased dramatically in recent years in the United States and other Western populations, and are now commonly prescribed in elderly women, according to background information in the article. "Esophagitis [inflammation of the esophagus] is a known adverse effect of bisphosphonate use, and recent reports suggest a link between bisphosphonate use and esophageal cancer, but this has not been robustly investigated," the authors write. "Large studies with appropriate comparison groups, adequate follow-up, robust characterization of bisphosphonate exposure, and information on relevant confounders are required to determine whether bisphosphonates increase esophageal cancer risk."

Chris R. Cardwell, Ph.D., of Queen's University Belfast, United Kingdom, and colleagues investigated the association between bisphosphonate use and esophageal cancer by extracting data from the UK General Practice Research Database of patients treated with oral bisphosphonates, along with a group of patients not treated with these drugs (control cohort), between January 1996 and December 2006. Average follow-up time was 4.5 and 4.4 years in the bisphosphonate and control cohorts, respectively.

Excluding patients with less than 6 months follow-up, there were 41,826 members in each group (81 percent women; average age, 70.0 years). One hundred sixteen esophageal or gastric cancers (79 esophageal) occurred in the bisphosphonate cohort and 115 (72 esophageal) in the control cohort. Analysis of the incidence of these cancers among the bisphosphonate and control groups found no difference in risk of esophageal and gastric cancer combined between the cohorts for any bisphosphonate use or risk of esophageal cancer only. There also was no difference in risk of esophageal or gastric cancer by duration of bisphosphonate intake.

"In conclusion, in the UK GPRD patient population we found no evidence for a substantially increased risk of esophageal (or gastric) cancer in persons using oral bisphosphonates. These drugs should not be withheld, on the basis of possible esophageal cancer risk, from patients with a genuine clinical indication for their use," the authors write.


'/>"/>

Contact: Chris R. Cardwell, Ph.D.
c.cardwell@qub.ac.uk
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. The private sale of drugs in public hospitals
2. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
3. Adapting to clogged airways makes common pathogen resist powerful drugs
4. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
5. Drugs That Shift Cells Energy Find New Purpose
6. FDA Tightens Controls on Anemia Drugs
7. FDA Issues Warning on Key Asthma Drugs
8. Two Tulsa Pharmacies Penalized for Missing Prescription Drugs
9. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
10. Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed
11. Scans Might Monitor Success of Alzheimers Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... BC (PRWEB) , ... March 29, 2017 , ... ... makeover services with or without a referral to new patients from Burnaby, BC. ... or other full mouth reconstruction services, can see the esteemed team at ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without ... efficiently, compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... as it continues developing an ANSI-approved, consensus-based American National Standard for Good ... to publish the first ANSI-approved GMP standard for dietary supplements this spring, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology: